https://www.selleckchem.com/pr....oducts/trastuzumab.h
9 ± 0.9 to 0.2 ± 0.6, 0.5 ± 0.9, 1.0 ± 1.2, and 1.3 ± 1.4 at the same time points. There was no statistically significant difference in BCVA, IOP, and medication reduction between the two groups. CLASS combined with or without phacoemulsification was equally safe and effective, but yielded more modest results in our population. CLASS combined with or without phacoemulsification was equally safe and effective, but yielded more modest results in our population.To improve women's access to pre-exposure prophylaxis (PrEP) in family plan